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SI Methods
Statement of Ethics and Regulations. PBMCs from HIV+ patients
or healthy donors were collected according to protocols ap-
proved by Institutional Review Boards of Massachusetts General
Hospital and California Institute of Technology. In vitro and
in vivo studies were performed as per the regulations of the
Institutional Biosafety Committees. All of the in vivo experi-
ments were performed as per the regulations of the Institutional
Animal Care and Use Committee.
Cell Lines and Primary Cells. HEK-293T (CRL-3216) cells and
Jurkat (TIB-152) cells were obtained from American Type
Culture Collection. Primary huPBMCs were obtained from
University of California, Los Angeles, Center for AIDS Research
Virology Core. HLA-typed huPBMCs were obtained from
ReachBio LLC, Key Biologics Inc., and Fred Hutchinson Cancer
Research Center Core for Excellence in Hematology. HLA type
was confirmed using allele-specific sequence specific primer
(SSP) assay fromOneLambda. GXR-B27+ cells were maintained
as described in ref. 1.
Cell-Culture Conditions and Media. HEK-293T cells were main-
tained in DMEM (Corning Cellgro) supplemented with 10% FBS
(Sigma or Corning) and penicillin/streptomycin (Corning) (D10).
Jurkat cells and GXR-B27+ cells were maintained in RPMI 1640
(Corning Cellgro) supplemented with 10% FBS and penicillin/
streptomycin (R10). Primary huPBMCs were thawed in R10,
coated on tissue culture-treated plates coated with 1 μg/mL anti-
CD3 functional grade antibody (eBiosciences), and cultured in
R10 supplemented with 1 μg/mL anti-CD28 functional grade
antibody (eBiosciences) and 40 U/mL human recombinant IL-2
(Miltenyi Biosciences). All of the cells were cultured at 37 °C
with 5% CO2 (Thermo Scientific). At the end of activation, the
cell population was >95% CD3+, consisting of CD4+ and CD8+
T cells (Fig. S1D). This cell population was used for transduction
and subsequent in vitro or in vivo assays.
TCR Cloning. To clone immunodominant TCRs from B27-KK10–
specific CTLs from patients, CD3+CD8+dextramer+ live singlet
cells were sorted using a FACS Aria II (BD Bioscience) directly
into RLT buffer supplemented with 1% β-mercaptoethanol and
used for RNA extraction as per the manufacturer’s instructions
(Qiagen). TCRα/β chains were amplified by 5′ rapid amplification of
cDNA ends as per the manufacturer’s protocol (Clontech) using
universal forward and gene-specific reverse primers in two rounds of
PCR (Cα-outer: 5′-GTCCATAGACCTCATGTCTAGCACAG-3′,
Cα-inner: 5′-ATACACATCAGAATCCTTACTTTG-3′, Cβ-outer:
5′-TGTGGCCAGGCACACCAGTGTGGCC-3′, Cβ-inner: 5′-
GGTGTGGGAGATCTCTGCTTCTGA-3′). Amplification was
detected by gel electrophoresis using 2% agarose gels stained
with Gel Green (Biotium). Amplified PCR product was purified
(Clontech) and cloned in pCR4-TOPO (Life Technologies).
Presence of insert was verified using colony PCR. The PCR
product was sequenced (Laragen). The Vα and Vβ families were
determined using IMGT V-Quest tool (2). Upon determining
the sequences, individual TCR chains were either assembled
using InFusion HD cloning kit (Clontech) or synthesized using
gBlocks (Integrated DNA Technologies) and cloned in pMSCV-
LNGFR using NotI–BamHI (New England Biolabs) and Mighty
Ligase mix (Clontech) and transformed in DH5α Escherichia coli
(Zymo). Individual clones were confirmed by colony PCR using
Accustart Taq (Quanta), and plasmids were extracted using
Zyppy miniprep kit (Zymo) and verified by sequencing (Laragen).
Modified versions of the TCRs encoding murine constant regions
were synthesized as gBlocks (Integrated DNA Technologies) and
cloned as described above.
Vector Production and Transduction. RD114-pseudotyped retro-
viruses encoding for the B27-KK10–specific TCRs were pro-
duced in HEK-293T cells by transient transfection of three
plasmids—an MSCV-based shuttle plasmid (a gift from R. A. Morgan,
NIH, Bethesda), pHIT60, and pRD114. HEK-293T cells were
plated at 5 × 106 cells per 10 cm plate (Corning/BD Falcon) in
D10. The cells were transfected using TransIT-293 (Mirus
Bio) using the manufacturer’s protocol with 7.5 μg of shuttle
plasmid, 7.5 μg of pHIT60, and 5 μg of pRD114. The cell-free
supernatant was harvested 72 h later and filtered through a 0.45-μm
filter (EMD Millipore), aliquoted, and stored at −80 °C until
further use. To transduce primary human T cells, PBMCs were
first activated for 7 d as described previously. The cells were
mixed with retroviral vector at 1 × 106 cells per well in 12-well
nontissue culture-treated plates coated with 10 μg/mL Retronectin
(Clontech) and spinfected at 1,111 g for 1.5 h at room tem-
perature. The cells were incubated for 72 h posttransduction
and harvested for functional assays. Jurkat cells were trans-
duced in tissue culture-treated plates using the conditions.
Replication competent virus NL4-3 (obtained through the NIH
AIDS Reagent Program, Division of AIDS, NIAID, NIH from
Malcolm Martin) was prepared by transient transfection of
HEK-293T cells with full-length pNL4-3 using BioT (Bioland
Scientific). The escape mutant R2T was generated by site-directed
mutagenesis (New England Biolabs) of pNL4-3 and prepared as
described above. The viral supernatant was harvested at 72 h
posttransfection, filtered through a 0.45-μm filter, aliquoted, and
stored at −80 °C until use. The viruses were titered with ELISA
for p24 antigen (Zeptometrix) according to the manufacturer’s
protocol.
Antibodies, Dextramers, and Flow Cytometry. The following anti-
bodies were used to detect expression of surface markers:
anti-CD3–PE/Cy5 (clone UHCT1), anti-CD3–APC/Cy7 (clone
UHCT1), anti-CD4–PE (clone OKT4), anti-CD4–PE/Cy7 (clone
RPA-T4), anti-CD45–PacificBlue (clone HI30), anti-CD8–FITC
(clone HIT8a), anti-TCRαβ–FITC (clone IP26), and anti-
LNGFR–PE (clone ME20.4) (all from Biolegend). For intracellular
staining, the following antibodies were used: anti-IFNγ–
BrilliantViolet421 (clone 4S.B3) and anti-Perforin–BrilliantViolet421
(clone B-D48) (both from Biolegend). To detect surface expres-
sion of the TCR, B27-KK10-APC tetramers (NIH Tetramer
core facility) or B27-KK10-APC dextramers were used (3).
The staining protocol was as follows: Cells were harvested and
centrifuged in 96-well plates. Cells were stained with diluted
antibody and/or tetramer or dextramer mixtures in 10–50 μL
PBS + 2% FBS for 20 min in the dark. For tetramer and an-
tibody staining, the cells were stained at room temperature; for
antibody staining, the cells were incubated at 4 °C. Following staining,
the cells were washed once with PBS + 2% FBS and acquired on
MACSQuant10 (Miltenyi). For intracellular staining, cells were
first stained with antibodies against surface markers at 4 °C for
20 min and fixed using fixation buffer (Biolegend) for 20 min.
The cells were then permeabilized using the Permeabilization/
Wash buffer (Biolegend) three times and stained with antibodies
against intracellular cytokines at room temperature for 20 min.
For analyzing frequency of T cells in mouse blood, 20 μL of blood
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was subjected to red blood cell lysis (Biolegend) twice, washed
once with PBS + 2% FBS, and stained with 50 μL of antibody
mixture at 4 °C for 20–30 min. The cells were washed once and
resuspended in PBS + 2% FBS + 2% paraformaldehyde and
acquired on MACSQuant 10. The data were recorded as .fcs files
and analyzed on Flowjo v10 (TreeStar).
In Vivo Experiments.HuPBMCmice were constructed as described
in Fig. S7A. Primary human T cells from an HLA-B27+ healthy
donor were activated and transduced as described in SI Methods.
Upon determining the TCR expression by flow cytometry, each
arm was normalized to 2% dextramer+LNGFR+ cells by di-
lution with mock-transduced cells. The cells were resuspended at
10 × 106 cells per milliliter in culture medium supplemented with
40 U/mL IL-2 and kept on ice until injections. NOD/SCID/
IL2Rγc−/− mice (Jackson Laboratories), 6–8 wk old, were anes-
thetized using isoflurane and injected intraperitoneally with 3 ×
106 cells. At 2 wk postengraftment, peripheral blood was col-
lected from mice by retroorbital bleeding using hematocrit
capillaries (Drummond Scientific) in heparinized Capiject tubes
(Terumo) and analyzed by flow cytometry for the frequency of
CD3+, CD4+, and CD8+ T cells (Fig. S7B). Plasma was col-
lected and stored at −20 °C for viral load measurement. Mice
that showed >0.5% CD3+ cells in total peripheral blood lym-
phocytes were used for subsequent experiments. Upon con-
firming human T cell engraftment, the mice were challenged
with 500 ng p24 of NL4-3 by i.p. injection. Peripheral blood was
collected from mice by retroorbital bleeding every week and
subjected to flow cytometry analysis and plasma collection. The
viral load in plasma was determined by measuring p24 antigen by
ELISA (Zeptometrix) according to the manufacturer’s protocol.
To randomize the mice allocated to each arm, the following
steps were taken: All of the mice in each experiment were
numbered serially; mice were injected with transduced cells by
rotating each of the experimental arms after every mouse. After
the initial injection, the experimental arms were blinded, as only
mouse serial numbers were followed.
Statistics. To calculate functional avidity, the maximal %IFNγ+
cell frequency, %maximal dextramer+ geometric mean fluores-
cence intensity, or maximal %cytotoxicity values were fitted onto
a dose–response curve using least squares fit. The comparison of
cross-reactivity was done using ANOVA and univariate analysis
using the STATA package. To compare hCD4+ T cell fre-
quencies in mouse models, unpaired t test was used. The vari-
ances of each group were compared using the F test. Statistical
analyses were performed using GraphPad Prism (GraphPad
Software).
MD Simulations. TCR homology models were next aligned to one
of three ternary crystal structures (4G8G, 4G9D, 4G9F) featuring
B*27:01-KK10 bound to TCRs; alignment templates were cho-
sen based on the lowest TCR coordinate root-mean-square de-
viations between homology models and alignment templates.
After applying disulfide bond patches, ternary complexes were
solvated in TIP3P water molecules and ionized to reach bio-
mimetic (150 mM) concentrations of Na+ and Cl− ions, yielding
systems containing ∼100,000 atoms in total. The solvated TCRs
were then minimized via steepest descent for 50,000 steps and
subsequently equilibrated at 310 K with and without harmonic
protein heavy atom constraints in 5-ns runs, respectively. To
sample/optimize the pHLA–TCR interfaces, each ternary structure
was next subjected to a simple simulated annealing procedure,
whereby complexes were successively minimized across three
iterations of (i) 10,000 steepest descent minimization steps followed
by (ii) 10 ns of MD at slightly elevated temperature (315 K).
These optimized structures were then equilibrated at 310 K for an
additional 25 ns. Production simulations were seeded from final
equilibrated conformations of each of the five ternary pHLA–
TCR complexes and extended to 1 μs in length. All MD simula-
tions were conducted using the NAMD 2.11 simulation package in
the constant-temperature, constant-pressure ensemble (NPT);
temperature and pressure were constrained at 310 K and 1 atm
using a Langevin thermostat and Parrinello–Rahman barostat,
respectively. Direct-space interactions were computed with a
12 Å cutoff, while long-range electrostatics were treated with the
Particle Mesh Ewald method. Water molecules were constrained
using the SETTLE algorithm. Representative complex structures
were drawn from high population clusters derived from a hybrid
k-means/k-medoids approach included in MSMBuilder 2.0. In-
teratomic distances between specific KK10 and TCR residues were
used as a clustering metric. Rendering and energetic and SASA
analyses were conducted in VMD 1.9.2. FEP calculations were
completed around canonical-free and bound-state cycles using the
FEP plugin in NAMD. Alchemical conformations of WT/
mutant residues were generated with the VMDMutator plugin, and
binding free energy differences were calculated with the Zwanzig
equation over central λ-increments of 0.04 and terminal
λ-increments of descending magnitude. Alchemical moieties were
treated with soft-core potentials, and electrostatic contributions
were initiated at λ = 0.1. ΔΔG values were computed across 1-ns
windows and averaged over five independent simulation runs in
all cases.
As mentioned in the main text, the work of Ladell et al. (4)
suggested an important role for a specific TCR motif (the
TRBV6-5 TRBJ1-1 CDR3β) in the function of the three ternary
alignment TCR templates [Protein Data Bank (PDB) ID codes
4G8G/4G9D/4G9F]. Specifically, the authors reported this spe-
cific TCR configuration resulted in resistance to the L6M escape
mutation common to KK10. Though some similarities exist to
the TRBV6-5 TRBJ1-1 arrangement at the N-terminal portions
of our CDR3β sequences, the full motif is not present in CP27,
CP7.9, FC5.5, HC25, or HC27. Despite this fact, our simulations
and functional experiments both indicated robust binding to the
WT and L6M versions of the KK10 peptide, in four of the five
TCRs studied. CP27 represents a possible exception, though
TCR function is only partially diminished in that case with the
L6M mutation. It is important to emphasize that these ternary
alignment complexes (4G8G, 4G9D, and 4G9F) served only as
intermediaries in the model construction/optimization process;
initial aligned complexes were subjected to extensive minimiza-
tion, equilibration, annealing, and production MD simulation
before additional analysis. Our simulation procedure produced
diverse and stable KK10 epitopes with respect to TCR in-
teraction, and our functional and simulated cross-reactivity data
were in good agreement. We thus feel confident in the conclu-
sions drawn from our simulation data. The divergent means by
which control of escape mutations can evolve in TCRs (as seen
here for L6M) represent an interesting topic for future study.
1. Chen H, et al. (2012) TCR clonotypes modulate the protective effect of HLA class I
molecules in HIV-1 infection. Nat Immunol 13:691–700.
2. Brochet X, Lefranc MP, Giudicelli V (2008) IMGT/V-QUEST: The highly customized and
integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic
Acids Res 36:W503–W508.
3. Bethune MT, Comin-Anduix B, Hwang Fu YH, Ribas A, Baltimore D (2017) Preparation
of peptide-MHC and T-cell receptor dextramers by biotinylated dextran doping.
Biotechniques 62:123–130.
4. Ladell K, et al. (2013) A molecular basis for the control of preimmune escape variants
by HIV-specific CD8+ T cells. Immunity 38:425–436.
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Fig. S1. Expression of B27-KK10–specific TCRs in primary T cells. (A) MSCV-based retroviral vector expressing LNGFR and cloned TCRs. (B) Measurement of
transduction and TCR expression. Representative flow plots are shown. (C) Quantification of LNGFR+ (dark bars) and LNGFR+dextramer+ (light bars) by flow
cytometry. The graph is representative of >20 experiments performed with >3 PBMC donors. (D) Phenotype of activated and transduced cells as measured by
flow cytometry. (E) Flow cytometry plots showing Perforin loading in CD8+ cells as measured by flow cytometry. The cells were gated on the CD45+CD3+
LNGFR+ population and then gated on CD8+Perforin+ cells. (F) Intensity of Perforin staining in the Perforin+CD8+ cells among cells transduced with different
TCRs is shown. Bars represent geometric mean fluorescence intensity of Perforin.
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Fig. S2. Cytotoxicity assays used to quantify the ability of T cells transduced with HC–, FC–, and CP–TCRs by flow cytometry. (A) Representative flow cytometry
plots showing cytotoxicity mediated by B27-KK10–specific TCRs and the quantification of percentage survival of target cells. (B) Lack of nonspecific cytotoxicity
toward cells pulsed with KY9, a B27-restricted Gag epitope, or no peptide. (C) Lack of nonspecific cytotoxicity toward uninfected (GFP−) GXR-B27+ cells. Bars
represent mean ± SEM from four technical replicates from n = 1.
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Fig. S3. Surface expression and cytotoxicity induced by murinized TCRs. (A) Measurement of surface TCR expression in cells transduced with unmodified or
murine constant region (MCR) TCRs. Representative flow plots are shown. (B) Quantification of LNGFR+ (dark bars) and LNGFR+dextramer+ (light bars) by flow
cytometry. (C) Cytotoxicity induced by transduced T cells toward GXR-B27+ cells pulsed with KK10 peptide at 24 h. The overall dextramer+ cells were not
normalized in this assay.
Fig. S4. Evidence for KK10 dependence of virus inhibition by TCRs. (A) Cytotoxicity induced by transduced T cells toward GXR-B27+ cells infected with wild-
type NL4-3. (B) Cytotoxicity induced by transduced T cells toward GXR-B27+ cells infected with NL4-3 encoding the R2T mutant. All bars show percentage
survival of target cells and represent mean ± SD from four replicates.
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Fig. S5. Functional avidity of TCR-transduced cells. (A) Log EC50 measurements as calculated from Fig. 2E. The bars indicate mean ± SD from four replicates.
(B) EC50 values and goodness-of-fit values for least squares fit model. (C) Functional avidity measurements using cytotoxicity as a readout. The lines indicate least
squares fit. (D) The range of TCR expression used as a gate for measuring dextramer staining. (E) Representative flow cytometry plots showing dextramer
staining as a function of reduced dextramer concentrations. (F and G) Log EC50 values and least squares fit for antigen sensitivity of transduced Jurkat cells,
respectively.
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Fig. S6. Cytokine secretion induced by HC–, FC–, and CP–TCRs. The absolute values of cytokine secretion as measured by LEGENDPlex. The column on the left
indicates dilution of LNGFR+dextramer+ cells in each sample. Cytokines that do not show dose dependence on LNGFR+dextramer+ cells and/or are not dif-
ferentially induced by TCRs compared with F5 or mock are highlighted in blue. Cytokines that are induced by TCRs in a dose-dependent manner are highlighted
in red. Cytokines highlighted here in red are shown in Fig. 2D.
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Fig. S7. HuPBMC mouse model to test the ability of T cells transduced with HC– and CP–TCRs to suppress HIV infection in vivo. (A) Schematic to demonstrate
the establishment of the huPBMC mice and challenging them with HIV. (B) Representative flow cytometry plots demonstrating the gating strategy used to
quantify CD3+ and CD4+ or CD8+ cells from huPBMC mice. The plots also show representative mice showing CD4+ T cell depletion upon challenge with NL4-3.
(C) Frequency of CD4+ T cells in individual mice over 4 wk postchallenge with HIV. Data points represent individual mice from two independent experiments.
The mean data composite of these mice is shown in Fig. 3A.
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Fig. S8. MD simulations of pHLA–TCR structure and correlation with cytotoxicity. (A) Illustration of a ternary pHLA–TCR complex used in MD and FEP sim-
ulations, with HLA-B*27:01, wild-type KK10, and CP27 featured. (B) Correlation between cytotoxicity and computed binding free energy differences for
KK10 escape variants. Regression analysis was completed with bisquare weights.
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Table S2. Characteristics of immunodominant TCRs from HCs and CPs
Patient Subject ID Dominant TCR TRAV family TRBV family CRD3β Frequency
HC 701998 (CTR203) HC25 TRAV8-4*03 TRBV25 5′-CASSEADFEAF-3′ 13/37
HC 388031 HC27 TRAV19 TRBV27 5′-CASSGGLPYGYT-3′ 6/8
FC 529440 (BWH20) FC5.5 TRAV22 TRBV5.5 5′-CASSSPPNTEAF-3′ 12/12
FC 708126 FC4.3 TRAV14DV4 TRBV4.3 5′-CASSPGIFANEQF-3′ 11/17
CP 427146 (CR338) CP27 TRAV4 TRBV27 5′-CASSPRTGELF-3′ 11/15
CP 339145 (FEN33) CP7.9 TRAV8-4*03 TRBV7.9 5′-CASSLAGGDSYEQY-3 10/14
Vα and Vβ families, CDR3 regions, and their frequency among all Vβ chains from the immunodominant TCRs
are shown. The frequency of Vβ25 for CTR203 is from the Chen et al. (1) study.
1. Chen H, et al. (2012) TCR clonotypes modulate the protective effect of HLA class I molecules in HIV-1 infection. Nat Immunol 13:691–700.
Table S3. Parameters for homology models
TCR %Identity Template Resolution, Å R free Clash score R. outliers, %
CP27_alpha 92 4oziE 3.2 0.280 6 0.7
CP27_beta 95 3vxtD 2.5 0.271 18 0.3
CP7.9_alpha 92 4gkzA 2.4 0.294 22 1.4
CP7.9_beta 95 3vxsE 1.8 0.231 5 0.1
HC25_alpha 92 1j8hD 2.4 0.245 15 0.4
HC25_beta 93 2cdfB 2.3 0.285 8 0.7
HC27_alpha 92 4jrxD 2.3 0.269 4 0.6
HC27_beta 95 3vxtB 2.5 0.271 18 0.3
FC5.5_alpha 93 2ialA 1.9 0.277 9 0.7
FC5.5_beta 85 2ntsP 2.4 0.238 16 2.2
Homology model sequence information (including template IDs, quality assessment parameters, alignments,
and conservation/identity indicators) for the five TCRs featured in this work is included below. R. outliers,
Ramachandran outliers.
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